Global Drugs for Immunotherapy Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

By Product;

Monoclonal antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors and Others.

By Therapy Area;

Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases and Others.

By End User;

Hospitals & Clinics, Ambulatory Surgical Centers and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).
Report ID: Rn109513251 Published Date: October, 2024 Updated Date: November, 2024

Introduction

Global Drugs for Immunotherapy Market (USD Million), 2020 - 2030

In the year 2023, the Global Drugs for Immunotherapy Market was valued at USD 199,450.59 million. The size of this market is expected to increase to USD 427,326.07 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 11.5%.

The global market for immunotherapy drugs is experiencing rapid growth, driven by significant advancements in biotechnology, a rising prevalence of chronic diseases, and an increasing emphasis on personalized medicine. Immunotherapy, which harnesses the body’s immune system to fight diseases such as cancer, autoimmune disorders, and infectious diseases, represents a paradigm shift in treatment modalities. Unlike traditional therapies that directly target disease-causing agents, immunotherapy aims to enhance the body's natural defenses, offering a more targeted and often less toxic alternative.

Key segments within the immunotherapy market include monoclonal antibodies, checkpoint inhibitors, vaccines, and CAR-T cell therapy. Monoclonal antibodies are widely used for their ability to specifically target and neutralize pathogens or cancer cells, while checkpoint inhibitors have revolutionized cancer treatment by unleashing the immune system to attack tumors. CAR-T cell therapy, which involves engineering a patient's own T cells to better recognize and destroy cancer cells, has shown remarkable efficacy in certain blood cancers. Vaccines, both prophylactic and therapeutic, continue to play a crucial role in preventing and treating infectious diseases and some cancers.

Geographically, the immunotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America currently leads the market due to substantial healthcare expenditure, advanced medical research infrastructure, and a high adoption rate of new therapies. Europe follows closely, benefiting from strong regulatory support and significant investments in biopharmaceutical research. The Asia Pacific region is expected to witness the fastest growth, driven by increasing healthcare access, a large patient population, and rising investments in biotechnology. Latin America and the Middle East and Africa also present emerging opportunities due to improving healthcare infrastructure and growing awareness of immunotherapy benefits. This global landscape underscores the expanding reach and potential of immunotherapy as a transformative approach in modern medicine.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Therapy Area
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Global Drugs for Immunotherapy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Advancements in Biotechnology

        2. Rising Prevalence of Chronic Diseases

      2. Restraints
        1. High Cost of Treatment

        2. Immune-Related Adverse Events

      3. Opportunities
        1. Personalized Medicine

        2. Emerging Applications in Infectious Diseases

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Drugs for Immunotherapy Market, By Product, 2020 - 2030 (USD Million)
      1. Monoclonal antibodies
      2. Interferons
      3. Interleukins
      4. Vaccines
      5. Checkpoint Inhibitors
      6. Others
    2. Global Drugs for Immunotherapy Market, By Therapy Area, 2020 - 2030 (USD Million)
      1. Cancer
      2. Autoimmune & Inflammatory Diseases
      3. Infectious Diseases
      4. Others
    3. Global Drugs for Immunotherapy Market, By End User, 2020 - 2030 (USD Million)
      1. Hospitals & Clinics
      2. Ambulatory Surgical Centers
      3. Others
    4. Global Drugs for Immunotherapy Market, By Geography, 2020 - 2030 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. F. Hoffmann-La Roche Ltd
      2. Novartis AG
      3. Amgen, Inc
      4. AbbVie, Inc
      5. Merck & Co., Inc
  7. Analyst Views
  8. Future Outlook of the Market